PolyPid Ltd. filings document foreign private issuer disclosures for a biopharmaceutical company developing PLEX-based controlled-release therapeutics. Form 6-K reports furnish corporate updates, financial results, FDA and NDA-related disclosures for D-PLEX100, SHIELD II clinical and pharmacokinetic information, GMP inspection updates, and business-operation summaries.
The company’s regulatory record also covers capital-structure and governance matters, including ordinary-share sales agreement disclosures, legal opinions tied to share issuance, Form F-3 and Form S-8 registration statement references, shareholder meeting results, board composition, director compensation approvals, and risk and operating disclosures incorporated into its SEC registration framework.
PolyPid Ltd. reported a net loss of $7,728 thousand for the first quarter of 2026, slightly improved from $8,268 thousand a year earlier. Operating expenses totaled $7,760 thousand, driven mainly by research and development of D-PLEX₁₀₀, which is now under an initiated NDA submission to the FDA.
Cash and cash equivalents were $8,888 thousand as of March 31, 2026, with total current assets of $12,560 thousand. Shareholders’ equity stood at $8,780 thousand, supported by additional paid-in capital of $318,008 thousand. Management highlighted late-stage U.S. commercial partnership discussions and reiterated expectations that existing cash resources can fund operations into the second half of 2026.
PolyPid Ltd. filed an amendment to its Schedule 13G/A disclosing that Rosalind Advisors Inc., Rosalind Master Fund L.P., Steven Salamon and Gilad Aharon each report shared beneficial voting and dispositive power over 5,384,813 shares, representing 9.9% of the class based on 18,204,002 ordinary shares outstanding as of December 31, 2025.
The filing states 597,926 shares are directly held and an additional 4,786,887 shares are issuable upon exercise of warrants subject to a blocker that prevents exercise to the extent it would increase beneficial ownership above 9.99%. The advisor and named individuals disclaim beneficial ownership beyond their advisory roles.
Polypid Ltd. ownership update: Aurum Ventures M.K.I. Ltd. reports beneficial ownership of 5,001,561 Ordinary Shares, consisting of 3,550,133 outstanding shares plus 1,451,428 shares issuable upon currently exercisable warrants. The filing bases its percent on 19,083,236 Ordinary Shares outstanding as of February 19, 2026, yielding 24.4% of the class; the reporting person notes warrant "blocker" provisions that limit exercise above 9.9% at any time.
PolyPid Ltd. director Jacobovitz Yitzchak Shlomo has filed an initial Form 3, which is the baseline disclosure of his ownership in the company as a reporting insider. The filing shows no recent stock purchases, sales, or other transactions, and contains no derivative holdings.
PolyPid Ltd. director Robert Benjamin Stein reported his existing holdings of stock options to purchase Ordinary Shares. These options cover individual blocks such as 312 shares at an exercise price of 11.4000 per share expiring on 2033-05-05 and 6,500 shares at 4.2400 per share expiring on 2034-07-02. Another grant for 14,440 underlying shares has an exercise price of 2.6700 per share and expires on 2035-06-25, with vesting on a quarterly basis through 2029. Several earlier grants are already fully vested, reflecting established equity-based compensation rather than new market transactions.
PolyPid Ltd. has begun submitting a New Drug Application to the U.S. FDA for its lead product, D-PLEX₁₀₀, to prevent surgical site infections in patients undergoing colorectal surgery. The NDA is being filed under Fast Track designation, allowing a rolling review, and the first Chemistry, Manufacturing and Controls and nonclinical modules have been submitted, with the clinical section expected in the second quarter of 2026.
D-PLEX₁₀₀ uses PolyPid’s Kynatrix delivery technology to release the antibiotic doxycycline directly at the surgical site over 30 days. In the Phase 3 SHIELD II trial, it achieved a statistically significant 60% relative risk reduction in infection rates after abdominal colorectal surgery and has received Breakthrough Therapy Designation from the FDA. PolyPid is also advancing negotiations for a U.S. commercialization partnership.
PolyPid Ltd. executive Ori Warshavsky, Chief Operating Officer – US, reports his direct holdings of company equity. He holds several employee stock options to buy Ordinary Shares at exercise prices ranging from 2.6700 to 23.0700 per share, with expiration dates from 2031-08-09 through 2035-05-12.
These option grants vest on various quarterly schedules or are already fully vested, as described in the footnotes, and he also directly holds 267 Ordinary Shares.
PolyPid Ltd. director Dror-Darwish Nir reported existing option holdings in a Form 3. The filing lists six stock option grants over Ordinary Shares, with exercise prices ranging from 2.6700 to 23.0700 and expiration dates between 2030 and 2036. Footnotes state that most grants are already fully vested, while one grant made on June 25, 2025 vests quarterly through May 12, 2029.
PolyPid Ltd. Chief Financial Officer Jonathan Missulawin filed an initial ownership report listing multiple employee stock options over Ordinary Shares. These options cover various blocks of shares, including 64,500 underlying shares at an exercise price of 4.6400 and 42,000 underlying shares at 2.6700, with expirations ranging from 2027 to 2035. The filing records existing derivative holdings and does not show any stock purchases or sales.
PolyPid Ltd. director Barenholz Yechezkel reports his initial holdings in a Form 3. The filing shows direct ownership of 2,760 Ordinary Shares and several stock option awards over Ordinary Shares, with exercise prices ranging from $2.6700 to $23.0700 and expirations from 2031 to 2035. Footnotes explain that earlier grants are already fully vested, while a June 25, 2025 grant vests quarterly through May 12, 2029.